Evidence map›Paper›PMID 32486450›Full record

ArticleCancers2020

Characterization of a Myeloid Activation Signature that Correlates with Survival in Melanoma Patients.

Mirela Kremenovic, Nives Rombini, Alfred A Chan, Thomas Gruber, Lukas Bäriswyl, Delphine J Lee, Mirjam Schenk

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Mirela KremenovicInstitute of Pathology, Experimental Pathology, University of Bern, 3008 Bern, Switzerland.
Nives RombiniInstitute of Pathology, Experimental Pathology, University of Bern, 3008 Bern, Switzerland.
Alfred A ChanDivision of Dermatology, Department of Medicine, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
Thomas GruberInstitute of Pathology, Experimental Pathology, University of Bern, 3008 Bern, Switzerland.
Lukas BäriswylInstitute of Pathology, Experimental Pathology, University of Bern, 3008 Bern, Switzerland.
Delphine J LeeDivision of Dermatology, Department of Medicine, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.ORCID 0000-0003-0063-5295
Mirjam SchenkInstitute of Pathology, Experimental Pathology, University of Bern, 3008 Bern, Switzerland.
University of Bern · CHUCLA Medical Center · US

Funding

Foundation for Experimental Biomedicine Zürich MSHelmut Horten Foundation MSSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung SNSF 320030_176083
6 · The paper itself

Abstract

Understanding the cellular interactions within the tumor microenvironment (TME) of melanoma paved the way for novel therapeutic modalities, such as T cell-targeted immune checkpoint inhibitors (ICI). However, only a limited fraction of patients benefits from such therapeutic modalities, highlighting the need for novel predictive and prognostic biomarkers. As myeloid cells orchestrate the tumor-specific immune response and influence the efficacy of ICI, assessing their activation state within the TME is of clinical relevance. Here, we characterized a myeloid activation (MA) signature, comprising the three genes

Indexed as

innate immunitymelanomamyeloid cellsprognostic gene signaturetumor immunity

Identifiers

PMID32486450
PMCPMC7352688
OpenAlexW3031037879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.